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Autosomal dominant cerebral cavernous malformation (CCM) represents a genetic
disorder with a high mutation detection rate given that stringent inclusion criteria are
used and copy number variation analyses are part of the diagnostic workflow. Pathogenic
variants in either CCM1 (KRIT1), CCM2 or CCM3 (PDCD10) can be identified in 87–98%
of CCM families with at least two affected individuals. However, the interpretation of novel
sequence variants in the 5′-region of CCM2 remains challenging as there are various
alternatively spliced transcripts and different transcription start sites. Comprehensive
genetic and clinical data of CCM2 patients with variants in cassette exons that are
either skipped or included into alternative CCM2 transcripts in the splicing process
can significantly facilitate clinical variant interpretation. We here report novel pathogenic
CCM2 variants in exon 3 and the adjacent donor splice site, describe the natural history
of CCM disease in mutation carriers and provide further evidence for the classification
of the amino acids encoded by the nucleotides of this cassette exon as a critical region
within CCM2. Finally, we illustrate the advantage of a combined single nucleotide and
copy number variation detection approach in NGS-based CCM1/CCM2/CCM3 gene
panel analyses which can significantly reduce diagnostic turnaround time.
Keywords: cerebral cavernous malformations, novel CCM2 mutations, CCM2 transcript analyses, CNV analyses,
seizures, cerebral hemorrhage
INTRODUCTION
Cerebral cavernous malformations (CCMs; MIM: 116860, 603284, 603285) are mulberry-like
vascular lesions that are formed by thin-walled and densely packed endothelial channels (1, 2).
These low-flow sinusoidal convolutes are characterized by an impaired blood-brain-barrier due
to a complex dysfunction of the lining endothelial cells. As a result of recurrent bleeding events,
CCM patients often present with non-specific headaches, seizures and stroke-like symptoms (3).
Over the last years, however, CCMs have increasingly been identified as incidental findings due
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to the widespread use of high-resolution magnetic resonance
brain imaging (4). Since targeted therapies have not yet been
approved, conservative treatment still focuses on the control of
CCM-related complications. Surgical resection can be an option
for easily accessible symptomatic CCMs, cavernous lesions that
cause epilepsy or for deep CCMs that are either symptomatic
or have already led to intracerebral hemorrhage. Treatment of
CCM patients with brainstem CCMs is often difficult and the
risk of post-operative morbidity and mortality always needs to
be critically discussed before the indication for surgical resection
is made (4).
CCMs may occur sporadically or in an autosomal dominant
familial form. The prevalence of symptomatic hereditary CCM
has been estimated to be in the range of 1:5,400 to 1:6,200 in the
general population (5). Heterozygous germline loss-of-function
variants in one of the three genes CCM1/KRIT1 (MIM 604214),
CCM2/OSM/Malcavernin (MIM 607929), or CCM3/PDCD10
(MIM 609118) can be found in the vast majority of familial
CCM cases (5). The identification of a pathogenic variant is
not only important for the index case but also crucial for
genetic counseling of at-risk family members. The mutation
detection rate of current molecular genetic CCM1/CCM2/CCM3
analyses is 87–98% for families with two or more CCM patients
and up to 57–75% for index cases with multiple CCMs but
a negative family history (4–6). However, these high mutation
detection rates can only be realized with stringent inclusion
criteria and a comprehensive workflow for the detection of
single nucleotide variants (SNVs), small indels, and copy-number
variants (CNVs).
CCM2 nonsense, frameshift, and splice mutations can be
identified in about 13% of CCM cases that meet the inclusion
criteria (6). Furthermore, various CCM2 CNVs have been
reported for sporadic and familial CCM cases (7–14). One of
these-the deletion of exons 2 to 10 of CCM2 (LRG_664t2)-
is actually a founder mutation in the US population (10, 11).
The multiplex ligation-dependent probe amplification (MLPA)
technique has long been used as gold standard for copy number
quantification but the implementation of gene panel analyses has
opened new perspectives for detection of CNVs from NGS data.
In this study, we report two novel and one previously
published variants within a cassette exon of CCM2 and provide
evidence for their pathogenicity. In addition, we describe the
natural history of CCM disease in mutation carriers and illustrate
the advantages of a combined NGS-based SNV/CNV detection
workflow in CCM1/CCM2/CCM3 gene panel analyses.
MATERIALS AND METHODS
Genetic Analyses
Genetic analyses were performed with written informed consent
of all study participants according to the German Gene
Diagnostics Act and approval of the local ethics committee of
the University Medicine Greifswald (No. B119/10). Genomic
DNA was isolated from peripheral blood lymphocytes using the
NucleoSpin Blood L Kit (Macherey-Nagel, Düren, Germany).
Thirty-one probands were analyzed for pathogenic CCM1,
CCM2, or CCM3 variants by hybridization capture-based target
enrichment and next generation sequencing and another 2
patients were analyzed by Sanger sequencing as described
previously (6). All coding exons and exon-intron-boundaries
(± 20 bp) of CCM1 (exons 5 to 20 according to reference
sequence LRG_650t1), CCM2 (exons 1 to 10 according to
LRG_664t2 = exons 1 and 3 to 11 according to LRG_664),
and CCM3 (exons 3 to 9 according to LRG_651t1) were
defined as target regions in both approaches. Sequencing libraries
were prepared with Nextera Rapid Capture (Panel ID: 113402,
Illumina, San Diego, USA) or Agilent SureSelectQXT (Panel
ID: 3152261, Agilent Technologies, Santa Clara, USA) custom
enrichment kits according to the manufacturers’ instructions
and sequenced on a MiSeq instrument with 2 × 150 cycles
(Illumina, San Diego, USA). FASTQ files were generated
with the MiSeq reporter software v2.6.2 (MSR; Illumina, San
Diego, USA). The SeqNext module of the Sequence Pilot
software (v5.0.0, JSI Medical Systems, Ettenheim, Germany) was
used for read mapping, alignment and variant calling. Sanger
sequencing data were analyzed with the SeqPatient module
of the Sequence Pilot software. The Human Splicing Finder
3.1 (http://www.umd.be/HSF3/), Berkeley Drosophila Genome
Project (http://www.fruitfly.org/), NetGene2 (http://www.cbs.
dtu.dk/services/NetGene2/), MaxEntScan (http://hollywood.mit.
edu/burgelab/maxent/Xmaxentscan_scoreseq.html), and ASSP
(http://wangcomputing.com/assp/) tools were used for in silico
splice predictions.
CNV Analyses
The SeqNext module (v5.0.0, JSI Medical Systems, Ettenheim,
Germany) was used for CNV analyses in a read-depth approach
based on a previous report for other target genes (15). In brief,
all exons of CCM1, CCM2, and CCM3, as well as 17 control
fragments located on different chromosomes were defined as
regions of interest (ROIs). Sequencing data were mapped and
aligned to the target region with the SeqNext module. In a first
normalization step, the specific read depth of each target exon
and the average read depth of all control fragments were used
to calculate the relative product coverage (RPC) for each CCM1,
CCM2, andCCM3 exon. In addition to the patient sample, at least
five control samples from the same sequencing run were analyzed
in the same way. In a next step, each RPC of the patient sample
was normalized to the corresponding average reference RPC
that had been calculated from all control samples. Thresholds
of ≤ 70 and ≥ 130% were used for deletion and duplication
calling, respectively. The Salsa MLPA Kits P130-A3 and P131-
B1 were used according to the manufacturer’s instructions to
validate the CCM1, CCM2, and CCM3 deletions (MRC-Holland,
Amsterdam, The Netherlands).
CCM2 Transcript Analyses
RNA was isolated from peripheral blood lymphocytes using
the PAXgene Blood RNA Kit (PreAnalytiX, Hombrechtikon,
Switzerland). Three hundred nanogram of total RNA were
reverse described into cDNA using SuperScriptTM III Reverse
Transcriptase (Thermo Fisher Scientific, Waltham, USA). The
exons 1, 3, 4, and 5 (exon numbering according to LRG_664) of
the CCM2 transcript LRG_664t2 were amplified using specific
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forward (5′-GCGGCGATATGGAAGAGG-3′) and reverse
(5’-GCACCCTGAGGATGATATC-3′) primers (7, 16). PCR
products were size-separated by agarose gel electrophoresis and
visualized on a Gel DocTM EZ Imager (Bio-Rad, Hercules, USA).
The excised fragments were purified with the ZymocleanTM Gel
DNA Recovery Kit (Zymo Research, Freiburg, Germany) and
analyzed by Sanger sequencing.
RESULTS
In our present study, we included 33 CCM index cases
with multiple CCMs and/or a positive family history that
had been analyzed for pathogenic variants in CCM1, CCM2
or CCM3 between 2017 and 2019 (Table 1). As expected,
most patients with an autosomal dominant CCM disease were
heterozygous for a pathogenic or likely pathogenic CCM1 variant
(n = 18) (Table S1). Another four patients had pathogenic
CCM2 germline variants and two patients were CCM3 mutation
TABLE 1 | Overview of the CCM cohort.
n = 33
Sex: M/F 16/17
Mean age ± standard deviation in years (range) 32.6 ± 18.1
(1–67)
Clinical manifestation
Single/multiple CCM 4/29
(12.1%/87.9%)
Cerebral hemorrhage 6
(18.2%)
Seizures 6 (18.2%)
Positive family history# 17/33
(51.5%)
Overall mutation detection rate 24/33
(72.7%)
Mutation detection rate for patients with a positive familial history 16/17 (94%)
Mutation detection rate for patients with a negative family history 8/16
(50%)
Genotypes
Pathogenic CCM1 variant 18
Pathogenic CCM2 variant 4
Pathogenic CCM3 variant 2
#Since neuroimaging data were not available for some relatives of the CCM index cases,
the classification as familial CCM case is based on clinical symptoms of at-risk family
members that were suggestive of CCM disease (e.g., seizures, hemorrhagic stroke).
carriers (Table S1). The unexpected observation that three of the
four CCM2 mutations clustered in a cassette exon that can be
skipped in the splicing process prompted us to focus on these
CCM2 variants that had been identified in families 1–3 in more
detail (Table 2).
Clinical Data of Families 1–3
The index patient of family 1 (III/4, Figure 1A) was first admitted
to neurosurgery at the age of 25. He reported a 6-year history
of headaches and focal seizures with intermittent numbness and
tingling in his right arm and leg. Magnetic resonance imaging
(MRI) identified two small CCMs in his left frontal and right
occipital lobe as well as a large cavernoma in his left parietal
lobe (20 × 18 × 20mm). The latter was resected by minimally
invasive microsurgery. Histological evaluation confirmed CCM
diagnosis. At the age of 28, the frequency of the index patient’s
seizures increased again, and the anti-epileptic therapy was
intensified. However, it was not possible to prevent seizures with
levetiracetam at maximum dosage of 2 × 1,500mg. Since an
increase in the size of the left frontal CCM (Figures 1B,C) was
noticed, it was finally resected by neurosurgery at the age of
33. At last follow-up at the age of 35 years, he still reported
epileptic seizures and two novel CCMs were identified in his right
frontal lobe and cerebellum. Anti-epileptic therapy was modified
to a combination of brivaracetam, lacosamide, perampanel, and
eslicarbazepine acetate.
Patient III/4 reported a positive family history for CCMs. His
eldest brother (III/2) has had trigeminal neuralgia since the age
of 23, and six cavernous lesions were identified on his MRI. The
index patient’s second brother (III/3) became symptomatic with
three focal to bilateral tonic-clonic seizures at the age of 32. One
cavernous lesion of 25 × 25 × 20mm in his left frontal lobe
demonstrated signs of an acute hemorrhage and was resected by
neurosurgery. In addition, at least seven small CCMs were found
in both hemispheres. Two cavernous malformations were also
identified in his yet asymptomatic 10-year old son (IV/1) at the
age of five. The index patient’s father (II/5) had a stroke at the age
of 33 and reported chronic headaches. Because of his pacemaker,
no MRI data were available for him. Furthermore, the index
patient’s paternal grandmother (I/2) had chronic headaches, and
two cousins of his father (II/2, II/3) had seizures.
The 46-year-old female index patient of family 2 (II/2,
Figure 2A) reported a 11/2-year history of chronic headaches
and recurrent attacks of vertigo that had lasted up to 1min.
MRI identified two CCMs located in her cerebellum and frontal
lobe. Since her paternal aunt (I/1, Figure 2A) had a CCM
bleeding, she was classified as familial CCM case. The male
TABLE 2 | Overview of the pathogenic CCM2 SNVs and indel variants reported in our present study.
Family
number
Exon (LRG_664) Exon (LRG_664t2) Nucleotide change Amino acid change Mutation type References
1 Ex 3 Ex 2 c.204+1G>A p.(Pro11_Lys68del) Splice site variant NOVEL
2 Ex 3 Ex 2 c.169dupA p.(Arg57Lysfs*8) Frameshift variant NOVEL
3 Ex 3 Ex 2 c.134_135delTG p.(Val45Glyfs*6) Frameshift variant (17)
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FIGURE 1 | (A) Pedigree of family 1. The index case (III/4) is marked with an arrow. Black filled symbols represent patients with CCMs, gray striped symbols indicate
relatives with neurological symptoms that are suggestive for CCM. Deceased family members are crossed out. Red stars indicate heterozygous carriers of the
pathogenic CCM2 splice variant c.204+1G>A. (B,C) Representative axial T2-weighted (B) and sagittal T1-weighted (C) MR images of the index case at the age of
32. (D) Schematic exon-intron structure of CCM2 and selected protein-coding CCM2 transcripts that are listed in the ENSEMBL database. ENST00000258781.10
and ENST00000541586.5 are both expressed in blood lymphocytes but ENST00000541586.5 in which exon 3 is skipped is less abundant in brain or blood vessels.
(E) Skipping of exon 3 on the c.204+1G>A CCM2 allele was confirmed by RT-PCR and cDNA sequencing. Lane 1: size marker, lane 2: control sample, lane 3:
patient III/4. E, exon.
index patient of family 3 (II/1, Figure 2B) had five CCMs
located in both hemispheres and became symptomatic at the age
of 30 with focal to bilateral tonic-clonic seizures. A sufficient
seizure control could be achieved by levetiracetammonotherapy.
The patient appears to be a sporadic CCM case since no
neurological symptoms that would have been indicative for
a CCM disease were reported for his maternal and paternal
lineage. However, a cryptic familial case cannot be excluded
since his father died of colorectal cancer at the age of 75
without molecular genetic analysis and the index patient’s 71-
year-old asymptomatic mother decided against predictive genetic
testing or MRI.
Genetic Analyses for Families 1–3
A novel substitution at position +1 of the highly conserved
donor splice site of exon 3 was identified in family 1 [LRG_664t2:
c.204+1G>A]. In silico predictions indicated disruption of
normal CCM2 splicing. Therefore, we decided to perform
additional transcript analyses. RT-PCR demonstrated skipping of
exon 3 on the mutant CCM2 allele (Figures 1D,E). Moreover,
a heterozygous SNP in exon 3 that was located in cis with the
CCM2 splice donor variant could not be identified by cDNA
sequencing indicating complete exon skipping. The loss of exon
3 leads to an in-frame deletion of 58 amino acids on protein level
[LRG_664p2: p.(Pro11_Lys68del)]. It is noteworthy to mention
Frontiers in Neurology | www.frontiersin.org 4 November 2019 | Volume 10 | Article 1219
Much et al. Novel Pathogenic CCM2 Variants
FIGURE 2 | Pedigrees of families 2 (A) and 3 (B). Arrows indicate the index cases in each family. (C,D) Sanger sequencing validation of pathogenic CCM2 variants
identified in family 2 (c.169dupA; C) and family 3 (c.134_135delTG; D). Nucleotide and protein sequences are shown above each chromatogram.
that this alteration involves the first ten amino acids of the PTB
domain of CCM2. Targeted CCM2 sequence analyses of blood
samples from multiple affected family members (III/2; III/3;
II/5; IV/1) demonstrated co-segregation of the splice site variant
with CCM disease in family 1. According to the latest ACMG
guidelines for the interpretation of sequence variants (18), the
splice site variant was classified as pathogenic.
CCM2 loss-of-function variants were also found in families
2 and 3. A novel pathogenic 1-bp duplication [LRG_664t2:
c.169dupA; LRG_664p2: p.(Arg57Lysfs∗8)] was detected in the
blood sample of the index patient of family 2 (Figure 2C)
and a 2-bp deletion [LRG_664t2: c.134_135delTG; LRG_664p2:
p.(Val45Glyfs∗6)] was identified in family 3 (Figure 2D). The
latter had previously been described in an Italian CCM family
(17) and was listed as likely pathogenic in the ClinVar database
(ClinVar-ID: 590648). Unfortunately, a blood sample from the
maternal aunt of the index patient in family 2 was not available to
test for the CCM2 variant. Of note, neither the two frameshift
variants in exon 3 nor the CCM2 splice site variant that had
been identified in family 1 are listed in the Genome Aggregation
Database (gnomAD) which contains 125,748 whole-exome and
15,708 whole-genome datasets.
CNV Detection From NGS Data
Besides SNVs and small indels that can be found in exon 3
of CCM2, a complete in-frame deletion of this exon has been
reported in the literature (10, 16). Therefore, we analyzed the
available NGS data of the CCM index cases of our cohort in a
combined workflow for SNVs and CNVs. Notably, we did not
detect a deletion of exon 3 of CCM2 but three other CNVs in
31 evaluated samples. In particular, we found a heterozygous
deletion of the exons 4 and 5 of CCM2 (exon numbering
according to LRG_664) in a 40-year-old symptomatic CCM
patient (Figures 3A,B). The relative product coverage ratios
(RPC ratios) of both exons were reduced to 52 and 49%,
respectively. In addition, heterozygous deletions of the exons 1 to
6 of CCM1 and of the exons 8 and 9 of the CCM3 gene (5) were
detected in two other CCM patients. RPC ratios were reduced
to 49–63 and 41–43%, respectively (Figures S1A–C). All three
CNVswere verified byMLPA analysis. Our data demonstrate that
apparently mutation-negative CCM patients always have to be
analyzed for CNVs and that a combined NGS-based SNV/CNV
detection workflow can reduce the diagnostic turnaround time
since it renders time-consuming MLPA analyses unnecessary.
DISCUSSION
We here present comprehensive clinical and genetic data of three
CCM2 families with pathogenic variants in a cassette exon of
CCM2, provide further evidence for the classification of exon 3
as a critical region within CCM2, and describe our procedure for
NGS-based CNV analyses.
Familial CCM can have many clinical faces. Pathogenic
CCM1, CCM2, and CCM3 variants are associated with
incomplete and locus-specific penetrance of 63, 55, and
68%, respectively (19). In addition, expressivity even between
family members sharing the same pathogenic variant can be
extremely variable. CCM2 mutation carriers reported in this
study mainly became symptomatic in their third to fifth decade
of life. The mean age at first clinical symptoms of the four
symptomatic CCM2 mutation carriers of family 1 (II/5; III/2;
III/3; III/4) and the two index patients of family 2 and 3 was
30.2 years (range 19–44). Hence, it was slightly lower than that
described for other CCM2 patients before. The mean age of
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FIGURE 3 | (A) Identification of a deletion of exons 4 and 5 of the CCM2 gene by NGS-based CNV analysis. The ROIs and their relative product coverages are shown
in the upper histogram for control samples (blue) and the sample of the CCM proband (green). The ratios for the relative coverage of each ROI are shown in the lower
panel. Red lines indicate the detection threshold for deletions and duplications. As some exons of CCM1-3 have been joined to combined ROIs and alternative exons
are also included in the CNV analysis, the number of analyzed ROIs is not equal to the number of exons of CCM1-3. (B) Verification of the heterozygous CCM2
deletion by MLPA analysis.
onset reported by Denier and colleagues was 34.9 years (range
1–69) (19) and our group has observed a mean age at referral to
genetic testing of 40.8 years (range 16–71) (6). The mean number
of cavernous lesions in our symptomatic CCM cases was also
slightly lower (mean number: 5.3; range 2 to 8) than the mean
number of 6.6 CCM lesions identified on T2-weighted MRIs of
37 other CCM2mutation carriers described in the literature (19).
The identification of a pathogenic variant within a CCM
family allows predictive testing for at-risk family members.
The exclusion of a known familial variant relieves relatives of
anxieties and renders special clinical surveillance unnecessary.
However, interpretation of novel CCM2 variants-especially of
those in exon 3-can be challenging since there are several
alternatively spliced CCM2 transcripts. The full-length CCM2
protein with its 444 amino acids has two major functional
domains. While the phosphotyrosine binding (PTB) domain is
thought to be essential for binding to CCM1 (20), the function
of the harmonin-homology domain (HHD) at the C-terminus
has not yet been fully elucidated. However, another CCM2
transcript (ENST00000541586.5, Figure 1D) without exon 3,
which encodes for part of the PTB domain, is highly expressed in
blood lymphocytes and spleen but less abundant in brain or blood
vessels. Of note, in vitro studies have demonstrated that deletion
of the amino acids encoded by exon 3 abrogates formation of
a ternary CCM1/CCM2/CCM3 protein complex (16). Thus, the
alternative CCM2 transcript seems to be unable to compensate
for loss of the full-length CCM2 protein. To the best of our
knowledge, at least ten pathogenic CCM2 SNVs and small indel
variants in exon 3 have been described so far (Table S2). These
mutations account for ∼15% of all known CCM2 nonsense,
frameshift and splice mutations (HGMD Professional 2019.1).
Taken together, these data implicate that only the full-length
CCM2 protein but not an alternative isoform without the 58
amino acids encoded by exon 3 can maintain cerebrovascular
stability and quiescence in brain endothelial cells. Therefore,
exon 3 can be defined to encode for a “well-established
functional domain” according to the ACMG guidelines for
variant interpretation (18).
Molecular genetic analyses of the CCM1/CCM2/CCM3 genes
have long been performed in a step-wise approach. Sequencing
for identification of SNVs was followed by MLPA analyses for
CNV detection (6). CNVs have been defined as duplications and
deletions of at least 1 kb and belong-together with inversions
of the same size-to structural genome variants (21). In a
modern diagnostic sense, single exon deletions and duplications
(> 50 bp) are also classified as CNVs (22). More than 60
different single- and multi-exon deletions and duplications in
CCM1, CCM2, and CCM3 are currently listed in the Human
Gene Mutation Database (HGMD Professional 2019.1). The
widespread use of NGS gene panel analyses and the further
development of bioinformatic algorithms nowadays allow SNV
and CNV detection in a single NGS pipeline. The advantage of
such a comprehensive approach is the significant reduction of
costs and turnaround time when compared to sequential Sanger
sequencing and MLPA analyses. Additionally, NGS-based CNV
analyses enable a higher resolution and more precise breakpoint
detection (23). However, current gene panel analyses also have
limitations. We have recently identified a 24 kb inversion by
whole genome sequencing that includes exon 1 of CCM2 in a
family with multiple CCM cases (24). The detection of such
copy-neutral structural genomic rearrangements in targeted
gene panel approaches is extremely challenging and often
even impossible.
In conclusion, the results of our study demonstrate that
accurate phenotyping and genotyping are crucial for variant
interpretation in CCM1/CCM2/CCM3 gene panel sequencing
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and that CNV calling from NGS data can help to make the
analyses more effective.
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